Articles

Ibrutinib Monotherapy in Patients with Relapsed/Refractory Follicular Lymphoma

ASH 2014 – Castleman's Disease

Safety and Efficacy of Ibrutinib plus Rituximab in Relapsed Mantle-Cell Lymphoma

ASH 2014 – Castleman's Disease

Combination of Ibrutinib and BCL-2 or Spleen Tyrosine Kinase Inhibitors in Ibrutinib-Resistant Diffuse Large B-Cell Lymphoma

ASH 2014 – Castleman's Disease

Ibrutinib in Patients with Bortezomib-Refractory Mantle-Cell Lymphoma

ASH 2014 – Castleman's Disease

Ibrutinib in Relapsed/Refractory Mantle-Cell Lymphoma: 2-Year Results of Safety and Durability of Response

ASH 2014 – Castleman's Disease

The Role of Hepcidin in Multicentric Castleman Disease

ASH 2014 – Castleman's Disease

Idiopathic Castleman Disease: Clinical Features and Therapeutic Options

ASH 2014 – Castleman's Disease

Restoration of Health with Siltuximab in Multicentric Castleman Disease

ASH 2014 – Castleman's Disease

Siltuximab Efficacy in Multicentric Castleman’s Disease Is Independent of Baseline Symptom Burden

ASH 2014 – Castleman's Disease

Frontline Chemoimmunotherapy with Fludarabine/Cyclophosphamide/Rituximab versus Bendamustine/Rituximab in Advanced CLL: Final Analysis of the CLL10 Study

ASH 2014 – CLL

Page 131 of 143